ABVC Biopharma Q1 FY26 net loss widens 79% to $1.69 million

• ABVC Biopharma posted a net loss of $1.69 million for the three months ended March 31, 2026, widening 79% from a year earlier, while revenue was unchanged at no revenue.
• Operating loss widened to $1.57 million as operating expenses more than doubled to $1.57 million on higher stock-based compensation.
• Net interest expense narrowed to $45,612, down 78%, reflecting lower interest expense tied to converted notes.
• Working capital deficit widened to $4.74 million, while net cash used in operating activities increased 66% to $894,243.
• Management highlighted full repayment of the Lind Notes, ongoing efforts to collect licensing and collaboration amounts due, and plans to seek additional financing while managing expenses amid going-concern uncertainty.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-058104), on May 18, 2026, and is solely responsible for the information contained therein.